(Q36904910)

17 August 2017

1 reference

title

Clinical pharmacology of celecoxib, a COX-2 selective inhibitor (English)

1 reference

17 August 2017

1 reference

Katerina Antoniou

1

1 reference

17 August 2017

Michael Malamas

series ordinal

2

1 reference

17 August 2017

Alexandros A Drosos

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

1 reference

17 August 2017

8

1 reference

17 August 2017

11

1 reference

17 August 2017

1719-1732

1 reference

COX-2 in inflammation and resolution

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Prostanoids in nociception and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

The cloned capsaicin receptor integrates multiple pain-producing stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

The capsaicin receptor: a heat-activated ion channel in the pain pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Pharmacological analysis of cyclooxygenase-1 in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Localization of cyclooxygenase-2 in human sporadic colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Distinct functions of COX-1 and COX-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Pharmacodynamic of cyclooxygenase inhibitors in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Novel determinants of plaque instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

COX-2 inhibitors and their role in gynecology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

NSAIDs in neuroblastoma therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Single-dose and steady-state pharmacokinetics of celecoxib in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Modulation of celecoxib pharmacokinetics by food in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Transfer of celecoxib into human milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Quantification of infant exposure to celecoxib through breast milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Celecoxib versus diclofenac in the management of osteoarthritis of the knee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Novel insights and therapeutical applications in the field of inhibitors of COX-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Chemoprevention of colorectal cancer: two steps forward, one step back?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Recent progress in ankylosing spondylitis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Current treatment of juvenile rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Adalimumab for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Risk of cardiovascular events associated with selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Celecoxib and cardiovascular risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Cardiovascular risk associated with celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Selective COX-2 inhibitors and risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Understanding the NSAID related risk of vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

COX-2 inhibitors and the heart: are all coxibs the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Blood pressure effects of COX-2 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Celecoxib, rofecoxib, and acute temporary visual impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Drug Points: Cholestatic hepatitis in association with celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Acute hepatocellular and cholestatic injury in a patient taking celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Intracerebral hemorrhage following possible interaction between celecoxib and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Warfarin and celecoxib interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Exacerbation of inflammatory bowel disease associated with use of celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

Interstitial nephritis associated with celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

The role of COX-2 inhibitors in pain modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1719

10.1517/14656566.8.11.1719

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference